Mark Stolar

1.8k total citations
23 papers, 1.4k citations indexed

About

Mark Stolar is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Mark Stolar has authored 23 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Endocrinology, Diabetes and Metabolism, 10 papers in Molecular Biology and 5 papers in Surgery. Recurrent topics in Mark Stolar's work include Growth Hormone and Insulin-like Growth Factors (10 papers), Metabolism, Diabetes, and Cancer (10 papers) and Diabetes Treatment and Management (7 papers). Mark Stolar is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (10 papers), Metabolism, Diabetes, and Cancer (10 papers) and Diabetes Treatment and Management (7 papers). Mark Stolar collaborates with scholars based in United States. Mark Stolar's co-authors include Gerhard Baumann, Klaus Amburn, Charles P. Barsano, Robert Ćhilton, Thomas A. Buchanan, Thomas A. Buchanan, Byron J. Hoogwerf, Patrick J. Boyle, Mary Lee Vance and Michael O. Thorner and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Clinical Endocrinology & Metabolism and Diabetes Care.

In The Last Decade

Mark Stolar

22 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Stolar United States 16 1.1k 367 238 196 181 23 1.4k
K G Alberti United Kingdom 15 932 0.9× 267 0.7× 137 0.6× 241 1.2× 431 2.4× 19 1.5k
Michael Christopher Australia 12 434 0.4× 459 1.3× 105 0.4× 165 0.8× 393 2.2× 32 1.1k
N. O’Meara United States 17 637 0.6× 202 0.6× 109 0.5× 384 2.0× 180 1.0× 31 1.2k
E Zukowska-Szczechowska Poland 21 321 0.3× 480 1.3× 234 1.0× 143 0.7× 234 1.3× 95 1.5k
Steven J. Hurel United Kingdom 26 619 0.6× 541 1.5× 331 1.4× 309 1.6× 325 1.8× 49 1.8k
Olga T. Hardy United States 12 448 0.4× 271 0.7× 159 0.7× 325 1.7× 352 1.9× 19 1.2k
Shanmei Shen China 24 659 0.6× 485 1.3× 161 0.7× 312 1.6× 180 1.0× 70 1.7k
Ming‐Chia Hsieh Taiwan 24 449 0.4× 434 1.2× 169 0.7× 274 1.4× 286 1.6× 76 1.5k
Angela Doering Germany 17 503 0.5× 253 0.7× 216 0.9× 101 0.5× 267 1.5× 25 1.4k
Yingying Luo China 21 614 0.6× 500 1.4× 329 1.4× 341 1.7× 228 1.3× 74 1.5k

Countries citing papers authored by Mark Stolar

Since Specialization
Citations

This map shows the geographic impact of Mark Stolar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Stolar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Stolar more than expected).

Fields of papers citing papers by Mark Stolar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Stolar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Stolar. The network helps show where Mark Stolar may publish in the future.

Co-authorship network of co-authors of Mark Stolar

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Stolar. A scholar is included among the top collaborators of Mark Stolar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Stolar. Mark Stolar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gagliano‐Jucá, Thiago, et al.. (2024). #1706888 Hyperlipasemia Associated with Teprotumumab Infusion. Endocrine Practice. 30(5). S161–S162.
2.
Stolar, Mark, et al.. (2021). COVID-19-Induced Diabetic Ketoacidosis in an Adult with Latent Autoimmune Diabetes. Cureus. 13(1). e12690–e12690. 13 indexed citations
3.
Stolar, Mark, Steve Chen, & Michael Grimm. (2013). Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes. Diabetes Metabolic Syndrome and Obesity. 6. 435–435. 8 indexed citations
4.
Stolar, Mark. (2010). Addressing Cardiovascular Risk in Patients With Type 2 Diabetes: Focus on Primary Care. The American Journal of the Medical Sciences. 341(2). 132–140. 8 indexed citations
5.
Stolar, Mark. (2010). Glycemic Control and Complications in Type 2 Diabetes Mellitus. The American Journal of Medicine. 123(3). S3–S11. 260 indexed citations
6.
Stolar, Mark. (2010). Defining and Achieving Treatment Success in Patients With Type 2 Diabetes Mellitus. Mayo Clinic Proceedings. 85(12). S50–S59. 37 indexed citations
7.
Gavin, James R., Mark Stolar, Jeffrey S. Freeman, & Craig Spellman. (2010). Improving outcomes in patients with type 2 diabetes mellitus: practical solutions for clinical challenges.. PubMed. 110(5 Suppl 6). S2–14; quiz S15. 12 indexed citations
8.
Stolar, Mark & Robert Ćhilton. (2003). Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clinical Therapeutics. 25. B4–B31. 53 indexed citations
9.
Stolar, Mark. (2002). Insulin resistance, diabetes, and the adipocyte. American Journal of Health-System Pharmacy. 59(suppl_9). S3–S8. 27 indexed citations
10.
11.
Baumann, Gerhard, et al.. (1994). Heterogeneity of circulating growth hormone. Nuclear Medicine and Biology. 21(3). 369–379. 12 indexed citations
12.
Stolar, Mark. (1988). Atherosclerosis in diabetes: The role of hyperinsulinemia. Metabolism. 37(2). 1–9. 120 indexed citations
13.
Stolar, Mark & Gerhard Baumann. (1986). Secretory patterns of growth hormone during basal periods in man. Metabolism. 35(9). 883–888. 45 indexed citations
14.
Stolar, Mark, et al.. (1986). Big growth hormone forms in human plasma: Immunochemical evidence for their pituitary origin. Metabolism. 35(1). 75–77. 16 indexed citations
15.
Baumann, Gerhard, Mark Stolar, & Thomas A. Buchanan. (1986). The Metabolic Clearance, Distribution, and Degradation of Dimeric and Monomeric Growth Hormone (GH): Implications for the Pattern of Circulating GH Forms*. Endocrinology. 119(4). 1497–1501. 47 indexed citations
16.
Baumann, Gerhard & Mark Stolar. (1986). Molecular Forms of Human Growth Hormone Secreted in Vivo: Nonspecificity of Secretory Stimuli*. The Journal of Clinical Endocrinology & Metabolism. 62(4). 789–790. 51 indexed citations
17.
Baumann, Gerhard, Mark Stolar, & Thomas A. Buchanan. (1985). Slow Metabolic Clearance Rate of the 20,000-Dalton Variant of Human Growth Hormone: Implications for Biological Activity*. Endocrinology. 117(4). 1309–1313. 66 indexed citations
18.
Baumann, Gerhard, Mark Stolar, & Klaus Amburn. (1985). Molecular Forms of Circulating Growth Hormone during Spontaneous Secretory Episodes and in the Basal State*. The Journal of Clinical Endocrinology & Metabolism. 60(6). 1216–1220. 64 indexed citations
19.
Stolar, Mark, Gerhard Baumann, Mary Lee Vance, & Michael O. Thorner. (1984). Circulating Growth Hormone Forms after Stimulation of Pituitary Secretion with Growth Hormone-Releasing Factor in Man*. The Journal of Clinical Endocrinology & Metabolism. 59(2). 235–239. 34 indexed citations
20.
Stolar, Mark, Klaus Amburn, & Gerhard Baumann. (1984). Plasma “Big” and “Big-Big” Growth Hormone (GH) in Man: An Oligomeric Series Composed of Structurally Diverse GH Monomers*. The Journal of Clinical Endocrinology & Metabolism. 59(2). 212–218. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by K G Alberti Breakdown of academic impact, for papers by Michael Christopher Breakdown of academic impact, for papers by N. O’Meara Breakdown of academic impact, for papers by E Zukowska-Szczechowska Breakdown of academic impact, for papers by Steven J. Hurel Breakdown of academic impact, for papers by Olga T. Hardy Breakdown of academic impact, for papers by Shanmei Shen Breakdown of academic impact, for papers by Ming‐Chia Hsieh Breakdown of academic impact, for papers by Angela Doering Breakdown of academic impact, for papers by Yingying Luo
Rankless by CCL
2026